Compare Smith & Nephew plc (SNN) vs Unum Group Common Stock (UNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Unum Group Common Stock — how do they compare? Smith & Nephew plc trades at $28.38 (market cap $11.65B), while Unum Group Common Stock trades at $91.42 (market cap $14.48B). The key difference: Unum Group Common Stock is the larger of the two by market cap, and Smith & Nephew plc pays the higher dividend (2.85%). Which is the better fit depends on your goals — on Pluang, investors hold Smith & Nephew plc for 121 Days and Unum Group Common Stock for 0 Days on average.
| SNN | UNM | |
|---|---|---|
Market Cap | $11.65B | $14.48B |
Volume | 860,347 | 2,214,044 |
Sector | Health | Financials |
52-Week High | $37.17 | $96.57 |
52-Week Low | $26.42 | $70.66 |
Typical Hold Time | 121 Days | 0 Days |
Enterprise Value | $14.68B | $18.04B |
Dividend Yield | 2.85% | 2.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNN trades at $27.86, near a 52-week low, with a mixed technical signal. Revenue has grown from $5.2B in 2022 to $6.16B in 2025, with net income margin improving to 10.08%. Recent product launches like the EVOS PELVIC System highlight innovation, but the stock faces headwinds from analyst downgrades and CFO departure news.
The outlook is cautious; while fundamentals show steady growth and a reasonable P/E of 18.95, weak sentiment and technical pressure near lows suggest limited near-term upside. Risks include execution challenges and competitive threats, but long-term investors may find value if operational improvements materialize.
Unum Group (UNM) trades at $92.05, down 0.5% with neutral technical signals. The stock shows mixed earnings performance with Q1 2026 beating estimates but Q4 2025 and Q2 2026 missing expectations. Analyst consensus is positive with 50% buy ratings and a $101 price target representing 9.7% upside. The company maintains stable profitability with 5.31% net margin and recently announced a $1 billion share repurchase program to enhance shareholder returns.
UNM presents a balanced investment case with strong institutional support and shareholder-friendly capital returns, though earnings consistency remains a concern. The stock trades at reasonable valuations (P/E 21.36, P/S 1.15) with potential upside to analyst targets. Key risks include premium growth sustainability and claims experience volatility in the insurance operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Unum Group Common Stock
Unum Group provides workplace benefits, including disability, life, accident, critical illness, dental, and vision insurance, along with leave management services. It serves employers through its Unum US, Unum International, and Colonial Life segments, distributing coverage via brokers and independent agents.
Read more on UNM →
